Moreover, the design and development of new anti-VEGF signaling drugs continues, including the arylamide-5-anilinoquinazoline-8-nitro derivative a recent inhibitor of VEGFR2-kinase activity with in vitro anti-tumor and anti-angiogenic activity [38]. Here, KDR is linked to neoplasm.